IP Library › Granted Patent US 10,945,965
Granted Patent B2
US 10,945,965 · App. 14/364,859 · Granted Mar 16, 2021

Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof

Inventors: Agnes Pottier (Paris, FR); Laurent Levy (Paris, FR); Marie-Edith Meyre (Paris, FR)
Assignee: NANOBIOTIX
A61K9/5115A61K9/0009A61K9/51A61K33/24A61K41/0038A61K41/0052A61K49/00A61K49/04A61K51/1244A61N5/10A61K2123/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,945,965
App. No.
14/364,859
Granted
Mar 16, 2021
Kind
B2
Abstract

The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with a hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal's intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.

Claims (9)

1. A method of identifying or destroying a target cell in a mammal comprising administering a non-radioactive nanoparticle to a mammal and exposing said mammal to a radiation source, wherein the non-radioactive nanoparticle consists of a metal selected from gold (Au), silver (Ag), platinum (Pt), palladium (Pd), tin (Sn), tantalum (Ta), ytterbium (Yb), zirconium (Zr), hafnium (Hf), terbium (Tb), thulium (Tm), cerium (Ce), dysprosium (Dy), erbium (Er), europium (Eu), holmium (Ho), iron (Fe), lanthanum (La), neodymium (Nd), praseodymium (Pr), lutetium (Lu) and mixtures thereof that is fully covered with a hafnium oxide material or embedded therein and the radiation source is ionizing radiation.

2. The method according to claim 1 , wherein said target cell is a tumor cell, a stenosing cell or an immune system cell.

3. The method according to claim 2 , wherein said method comprises the application of a radiation source providing ionizing radiation in an amount and energy that destroys said target cell.

4. The method according to claim 1 , wherein the metal is gold (Au).

5. The method according to claim 1 , wherein the metal is platinum (Pt).

6. The method according to claim 1 , wherein the metal is tantalum (Ta).

7. The method according to claim 1 , wherein the metal is hafnium (Hf).

8. The method according to claim 1 , wherein the metal is zirconium (Zr).

9. The method according to claim 1 , wherein the metal is iron (Fe).

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 033827 FRAME: 0731. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 8, 2021
From: POTTIER, AGNÈS; LEVY, LAURENT; MEYRE, MARIE-EDITH
To: NANOBIOTIX S.A.
Reel/Frame 058045/0092 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2014
From: POTTIER, AGNES; LEVY, LAURENT; MEYRE, MARIE-EDITH
To: NANOBIOTIX
Reel/Frame 033827/0731 →
Priority Claims (1)
EP 11193968 · Dec 16, 2011 · regional
Continuity (2)
Provisional Application 61576437 · Dec 16, 2011
Related Publication 20140335015A1 · Nov 13, 2014
Cited By (2)
US 12,245,355 US 12,653,890